Chaoran Yu1,2,3, Yujie Zhang4. 1. Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200025, P.R. China chaoran_yu@sjtu.edu.cn yujiezhang@outlook.com. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200025, P.R. China. 3. Department of Gastrointestinal Surgery, Shanghai Minimally Invasive Surgery Center, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, P.R. China. 4. Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, P.R. China chaoran_yu@sjtu.edu.cn yujiezhang@outlook.com.
Abstract
The present study was to develop a prognostic nomogram to predict overall survival (OS) and cancer-specific survival (CSS) in early-onset colon cancer (COCA, age < 50). Patients diagnosed as COCA between 2004 and 2015 were retrieved from the surveillance, epidemiology, and end results (SEER) database. All included patients were assigned into training and validation sets. Univariate and multivariate analysis were used to identify independent prognostic variables for the construction of nomogram. The discrimination and calibration plots were used to measure the accuracy of the nomogram. A total of 11220 patients were included from the SEER database. The nomograms were established based on the variables significantly associated with OS and CSS using cox regression models. Calibration plots indicated that both nomograms in OS and CSS exhibited high correlation to actual observed results. The nomograms also displayed improved discrimination power than tumor-node-metastasis (TNM) stage and SEER stage both in the training and validation sets. The monograms established in the present study provided an alternative tool to both OS and CSS prognostic prediction compared with TNM and SEER stages.
The present study was to develop a prognostic nomogram to predict overall survival (OS) and cancer-specific survival (CSS) in early-onset colon cancer (COCA, age < 50). Patients diagnosed as COCA between 2004 and 2015 were retrieved from the surveillance, epidemiology, and end results (SEER) database. All included patients were assigned into training and validation sets. Univariate and multivariate analysis were used to identify independent prognostic variables for the construction of nomogram. The discrimination and calibration plots were used to measure the accuracy of the nomogram. A total of 11220 patients were included from the SEER database. The nomograms were established based on the variables significantly associated with OS and CSS using cox regression models. Calibration plots indicated that both nomograms in OS and CSS exhibited high correlation to actual observed results. The nomograms also displayed improved discrimination power than tumor-node-metastasis (TNM) stage and SEER stage both in the training and validation sets. The monograms established in the present study provided an alternative tool to both OS and CSS prognostic prediction compared with TNM and SEER stages.
Colorectal cancer (CRC) is one of the common malignant death-caused diseases worldwide [1]. In the United States, CRC patients were newly registered in approximately 130000 cases with over 50000 death reports [1]. In Europe, CRC is both the second common cause of death in the European Union with 215000 cases and second common cancer sites with 447000 cases [2]. In Singapore, CRC ranks top in incidence and second in cause of cancer death [3]. Meanwhile, the incidence and death rates of CRC have been increasing in China [4]. Although the incidence and death rates have been reduced in CRC patients older than 50, the incidence of early-onset CRC (age < 50) increases by 22% and the death rate increases by 13% in the United States during the last decade [1].Radical surgical intervention remains the primary treatment for CRC [5]. Nevertheless, approximately 25% of CRC patients develop recurrence or distant metastasis [6]. Intriguingly, combinational therapies of chemotherapy and targeted drugs have significantly improved the therapeutic benefits in CRC [7,8]. However, the intrinsic complexity of early-onset CRC remains largely unknown. Generally, early-onset tumors are more likely to be associated with germline genotypes. Hong et al. discovered seven genes (CYR61, UCHL1, FOS, FOSB, EGR1, VIP, and KRT24) as a susceptibility gene set associated with early-onset CRC patients [9]. Ågesen et al. indicated that CLC and IFNAR1 were differentially expressed between young and elderly CRC patients with respect to somatic gene expression, highlighting the genomic complexity associated with age [10]. Nevertheless, the overall prognosis of early-onset CRC remains largely constrained by clinical heterogeneity. Therefore, a refined nomogram system is needed to contribute to the prognosis evaluation of early-onset CRC. In fact, given the genomic-features and clinic-management variances between the colon cancer (COCA) and rectal cancer [11,12], the present study exclusively focused on COCA.Previously, the tumor-node-metastasis (TNM) cancer staging system of American Joint Committee on Cancer (AJCC) has been periodically updated for effective cancer management [13]. However, increasing studies indicated that other factors, including age, race, and tumor site have also been in association with tumor prognosis in individual case [10,14,15]. Therefore, it is needed to establish a prognostic indicator system specified for early-onset COCApatients.The nomogram-based statistical method has been widely implemented in prognosis-associated clinical studies with comparable results [16,17]. In fact, nomograms enable specifically individual survival scores by dynamically incorporating clinical variables with technical feasibility and reproducibility. However, nomograms for the prognosis of early-onset COCA have not been fully characterized.Because of this need, a prognostic nomogram based on the large population of COCA data retrieved from the surveillance, epidemiology, and end results (SEER) program (2004–2015) was developed to predict individualized survival in early-onset COCA.
Materials and methods
Patients
The clinicopathological data of all COCApatients were retrieved from the SEER program of the United States National Cancer Institute (NCI). SEER program is established to comprehensively collect clinical information on various cancer types for associated incidence, prevalence, and prognostic studies [18,19].Patients diagnosed with COCA from 2004 to 2015 were retrieved. The histological code [International Classification of Diseases for Oncology, Third edition (ICD-O-3)] and the cancer staging scheme (version 0204) were used to identify all the patients. The inclusion criteria were (1) tumor site was colon excluding rectum; (2) diagnosis had been microscopically confirmed; (3) age <50; (4) complete TNM stage information; (5) COCA was the first and the only cancer primary; (6) surgery had been performed. All the included patients were randomly assigned to a training set and validation set. The present study was performed with the data from SEER program and reference number 14622-Nov2017. No informed consent or institutional review board approval was required in the present study due to the public-available data of SEER.
Variables
Clinical variables of COCApatients were extracted, including age, sex, marital status, histological grade, tumor site, TNM stage, tumor size, SEER stage follow-up information, and corresponding death causes. Overall survival (OS) was the primary endpoint, defined as the time period from the diagnosis to the death or last follow-up. Cancer-specific survival (CSS) was the second endpoint, defined as the time period from the diagnosis to the death caused by COCA or censoring. Age and tumor size were transformed into categorical variables.
Construction of the nomogram
All the categorical variables were presented with frequencies and proportions, and analyzed by a chi-square test. The Kaplan–Meier method and log-rank test were used to analyze each potential prognostic variable. All significant variables from univariate analysis were subject to a multivariate Cox proportional hazards analysis. The construction of nomogram was based on the multivariate cox regression model by the R statistical package rms (R Foundation for Statistical Computing, Vienna, Austria).
Validation of the nomogram
The validation set was used for the validation of the nomogram by the discrimination, calibration, and bootstrap resampling. The concordance index (C-index) was used to measure the difference between the observed and predicted results from the constructed nomogram. Receiver operating characteristics curve (ROC) analysis was performed for sensitivity and specificity. We further compared the nomogram, the TNM stage, and the SEER stage using the C-index. Calibration plot was used to visualize the variance between nomogram-predicted prognosis and actual prognosis. The 45-degree line in a calibration plot was used as a perfect model to compare the actual outcomes. Furthermore, decision curve analysis (DCA) was used to depict the threshold probabilities ranges in comparison with TNM stage and SEER stage. All the statistical analyses were performed using R software version 3.3.0 (Vienna, Austria; www.r-project.org). P-value <0.05 was considered as statistically significant.
Results
Patient characteristics
A total of 11220 eligible cases were included in the present study with 7856 cases randomly assigned to the training set and 3364 into the validation set (Figure 1). 52.2% of all patients were married and 41.7% were unmarried (also including widowed, single, and divorced). For all the early-onset patients, 7780 were between 40 and 50 years old (69.3%), whereas 2383 were between 30 and 40 years old (21.2%). 1057 were younger than 30 years old (9.4%). The majority of race was white (73.1%). The most common tumor site for COCA in the present study was the sigmoid colon (35.3%), followed by appendix (14.7%) and cecum (13.8%) and ascending colon (12.4%). For tumor size, 2–5 cm was the most common type (38.7%), followed by 5–10 cm (30.7%). 52.5% of all the patients were N0 whereas 80.1% were M0 in AJCC stage system. 42.5% of all the patients were regional in SEER stage (Table 1).
Figure 1
Flow diagram of the included colon cancer patients
Table 1
The demographics and pathological characteristics of included patients
Variables
All patients
Training set
Validation set
P-value
n (%)
n (%)
n (%)
Total
11220 (100)
7856 (70)
3364 (30)
Marital status
0.236
Married
5862 (52.2)
4064 (51.7)
1798 (53.4)
Unmarried
4679 (41.7)
3315 (42.2)
1364 (40.5)
Unknown
679 (6.1)
477 (6.1)
202 (6.0)
Sex
0.172
Male
5552 (49.5)
3921 (49.9)
1631 (48.5)
Female
5668 (50.5)
3935 (50.1)
1733 (51.5)
Age
0.307
<30
1057 (9.4)
751 (9.6)
306 (9.1)
30–40
2383 (21.2)
1692 (21.5)
691 (20.5)
>40
7780 (69.3)
5413 (68.9)
2367 (70.4)
Race
0.021
White
8206 (73.1)
5700 (72.6)
2506 (74.5)
Black
1776 (15.8)
1297 (16.5)
479 (14.2)
Other
1101 (9.8)
768 (9.8)
333 (9.9)
Unknown
137 (1.2)
91 (1.2)
46 (1.4)
Grade
0.505
I
1595 (14.2)
1111 (14.1)
484 (14.4)
II
6658 (59.3)
4654 (59.2)
2004 (59.6)
III
1720 (15.3)
1233 (15.7)
487 (14.5)
IV
419 (3.7)
287 (3.7)
132 (3.9)
Unknown
828 (7.4)
571 (7.3)
257 (7.6)
Site
0.553
Appendix
1645 (14.7)
1161 (14.8)
484 (14.4)
Ascending colon
1390 (12.4)
950 (12.1)
440 (13.1)
Cecum
1552 (13.8)
1115 (14.2)
437 (13.0)
Descending colon
925 (8.2)
651 (8.3)
274 (8.1)
Hepatic flexure
364 (3.2)
247 (3.1)
117 (3.5)
Large intestine, NOS
199 (1.8)
133 (1.7)
66 (2.0)
Sigmoid colon
3959 (35.3)
2772 (35.3)
1187 (35.3)
Splenic flexure
359 (3.2)
255 (3.2)
104 (3.1)
Transverse colon
827 (7.4)
572 (7.3)
255 (7.6)
AJCC stage
0.96
I
2761 (24.6)
1926 (24.5)
835 (24.8)
II
2681 (23.9)
1877 (23.9)
804 (23.9)
III
3547 (31.6)
2495 (31.8)
1052 (31.3)
IV
2231 (19.9)
1558 (19.8)
673 (20.0)
AJCC T
0.725
T1
2346 (20.9)
1644 (20.9)
702 (20.9)
T2
1016 (9.1)
696 (8.9)
320 (9.5)
T3
5313 (47.4)
3724 (47.4)
1589 (47.2)
T4
2545 (22.7)
1792 (22.8)
753 (22.4)
AJCC N
0.548
N0
5891 (52.5)
4117 (52.4)
1774 (52.7)
N1
3001 (26.7)
2123 (27.0)
878 (26.1)
N2
2328 (20.7)
1616 (20.6)
712 (21.2)
AJCC M
0.853
M0
8989 (80.1)
6298 (80.2)
2691 (80.0)
M1
2231 (19.9)
1558 (19.8)
673 (20.0)
Tumor size
≤2cm
1912 (17.0)
1337 (17.0)
575 (17.1)
0.249
>2 to ≤5 cm
4343 (38.7)
3023 (38.5)
1320 (39.2)
>5 to ≤10 cm
3447 (30.7)
2452 (31.2)
995 (29.6)
>10 cm
534 (4.8)
360 (4.6)
174 (5.2)
NA
984 (8.8)
684 (8.7)
300 (8.9)
SEER stage
0.439
Localized
4054 (36.1)
2809 (35.8)
1245 (37.0)
Regional
4764 (42.5)
3359 (42.8)
1405 (41.8)
Distant
2402 (21.4)
1688 (21.5)
714 (21.2)
Establishment of the nomogram
Marital status, age, race, grade, site, TNM stage, tumor size, and SEER stage were significantly associated with OS by univariate analysis in the training set (Table 2). Further multivariate analysis indicated that marital status, race, grade, TNM stage, tumor size, and SEER stage were significantly associated with OS. Therefore, a nomogram of 3- and 5-year OS was established with the independent variables (Figure 2A). In addition, the prognostic values and clinicopathological characterization of patients with different marital status were displayed (Supplementary Figure S1 and Table S1). Moreover, each variable was also examined for CSS and therefore used to build a CSS nomogram as well (Table 3 and Figure 2B).
Table 2
Univariate and multivariate analyses of overall survival (OS) in the training set of early-onset colon cancer patients
Variables
Univariate analysis
Multivariate analysis
P-value
HR(95%CI)
P-value
Marital status
<0.001
Married
Reference
Unmarried
1.45(1.28–1.64)
<0.001
Unknown
1.39(1.06–1.82)
0.017
Sex
0.215
Male
Female
Age
0.027
<30
Reference
30–40
0.96(0.73–1.26)
0.769
>40
1.10(0.86–1.41)
0.452
Race
<0.001
White
Reference
Black
1.20(1.04–1.39)
0.015
Other
0.91(0.74–1.12)
0.371
Unknown
9.03e−07(0–Inf)
0.982
Grade
<0.001
I
Reference
II
1.22(0.91–1.65)
0.187
III
2.02(1.49−2.75)
<0.001
IV
2.22(1.56–3.16)
<0.001
Unknown
1.66(1.10–2.51)
0.016
Site
<0.001
Appendix
Reference
Ascending colon
1.23(0.89–1.70)
0.214
Cecum
1.16(0.85–1.59)
0.348
Descending colon
0.98(0.70–1.40)
0.930
Hepatic flexure
1.12(0.73–1.71)
0.603
Large intestine, NOS
1.31(0.82–2.10)
0.256
Sigmoid colon
0.89(0.66–1.21)
0.467
Splenic flexure
1.10(0.74–1.63)
0.639
Transverse colon
1.07(0.75–1.51)
0.716
AJCC stage
<0.001
I
–
II
–
III
–
IV
–
AJCC T
<0.001
T1
Reference
T2
2.77(1.37–5.63)
0.005
T3
4.21(2.19–8.10)
<0.001
T4
5.54(2.86–10.72)
<0.001
AJCC N
<0.001
N0
Reference
N1
1.73(1.41–2.11)
<0.001
N2
2.34(1.91–2.86)
<0.001
AJCC M
<0.001
M0
Reference
M1
2.89(1.93–4.31)
<0.001
Tumor size
<0.001
≤2cm
Reference
>2 to ≤5 cm
1.15(0.83–1.60)
0.389
>5 to ≤10 cm
1.16(0.84–1.62)
0.368
>10 cm
1.48(1.00–2.20)
0.0497
SEER stage
<0.001
Localized
Reference
Regional
1.61(1.13–2.28)
0.008
Distant
3.03(1.80–5.12)
<0.001
Figure 2
Nomograms for early-onset colon cancer patients
(A) Nomograms for 3- and 5-year-associated OS. (B) Nomograms for 3- and 5-year-associated CSS.
Table 3
Univariate and multivariate analyses of Cancer-specific survival (CSS) in the training set of early-onset colon cancer patients
Variables
Univariate analysis
Multivariate analysis
P-value
HR(95%CI)
P-value
Marital status
<0.001
Married
Reference
Unmarried
1.40(1.23–1.60)
<0.001
Unknown
1.34(1.01–1.78)
0.041
Sex
0.352
Male
Female
Age
0.054
<30
Reference
30–40
0.97(0.73–1.29)
0.829
>40
1.09(0.84–1.41)
0.508
Race
<0.001
White
Reference
Black
1.19(1.02–1.39)
0.028
Other
0.95(0.78–1.17)
0.652
Unknown
0.90(0–Inf)
0.984
Grade
<0.001
I
Reference
II
1.32(0.96–1.82)
0.092
III
2.27(1.64–3.16)
<0.001
IV
2.33(1.60–3.41)
<0.001
Unknown
1.79(1.15–2.78)
0.010
Site
<0.001
Appendix
Reference
Ascending colon
1.09(0.78–1.52)
0.613
Cecum
1.01(0.73–1.39)
0.953
Descending colon
0.85(0.59–1.21)
0.367
Hepatic flexure
1.05(0.68–1.61)
0.830
Large intestine, NOS
1.20(0.75–1.94)
0.450
Sigmoid colon
0.80(0.59–1.09)
0.156
Splenic flexure
0.94(0.63–1.42)
0.778
Transverse colon
0.94(0.66–1.34)
0.730
AJCC stage
<0.001
I
–
II
–
III
–
IV
–
AJCC T
<0.001
T1
Reference
T2
4.12(1.66–10.18)
0.002
T3
6.50(2.77–15.24)
<0.001
T4
8.59(3.64–20.23)
<0.001
AJCC N
<0.001
N0
Reference
N1
1.88(1.52–2.32)
<0.001
N2
2.55(2.06–3.16)
<0.001
AJCC M
<0.001
M0
Reference
M1
3.35(2.17–5.17)
<0.001
Tumor size
<0.001
≤2cm
Reference
>2 to ≤5 cm
1.11(0.79–1.55)
0.565
>5 to ≤10 cm
1.13(0.80–1.59)
0.484
>10 cm
1.51(1.01–2.27)
0.046
SEER stage
<0.001
Localized
Reference
Regional
1.79(1.20–2.66)
0.004
Distant
3.16(1.77–5.66)
<0.001
Nomograms for early-onset colon cancer patients
(A) Nomograms for 3- and 5-year-associated OS. (B) Nomograms for 3- and 5-year-associated CSS.
Nomogram validation
The nomograms were both internally and externally validated. The internal validation was performed via the training cohort with the C-index as 0.835 (95%CI, 0.823–0.847) in OS and 0.851 (95%CI, 0.840–0.862) in CSS, respectively (Table 4). The external validation was performed via the validation cohort with the C-index as 0.848 (95%CI, 0.831–0.865) in OS and 0.863 (95%CI, 0.847–0.879) in CSS, respectively. Calibration plots of the validations of OS and CSS nomograms indicated highly correlations between the predicted and observed results (Figures 3 and 4).
Table 4
Comparison of C-indexes between the nomograms, TNM, and SEER stages in early-onset colon cancer patients
Training set
Validation set
HR
95%CI
P-value
HR
95%CI
P-value
OS
Nomogram
0.835
0.823–0.847
0.848
0.831–0.865
SEER stage
0.780
0.767–0.793
<0.001
0.798
0.780–0.816
<0.001
TNM 7th stage
0.818
0.806–0.830
0.027
0.84
0.823–0.857
0.126
CSS
Nomogram
0.851
0.840–0.862
0.863
0.847–0.879
SEER stage
0.795
0.783–0.807
<0.001
0.813
0.795–0.831
<0.001
TNM 7th stage
0.835
0.823–0.847
0.034
0.858
0.842–0.874
0.189
Figure 3
Calibration plots of the training and validation sets for the OS-associated nomograms
(A,B) The calibration plots of the training set in 3- and 5-year OS. (C,D) The calibration plots of the validation set in 3- and 5-year OS.
Figure 4
Calibration plots of the training and validation sets for the CSS-associated nomograms
(A,B) The calibration plots of the training set in 3- and 5-year CSS. (C,D) The calibration plots of the validation set in 3- and 5-year CSS.
Calibration plots of the training and validation sets for the OS-associated nomograms
(A,B) The calibration plots of the training set in 3- and 5-year OS. (C,D) The calibration plots of the validation set in 3- and 5-year OS.
Calibration plots of the training and validation sets for the CSS-associated nomograms
(A,B) The calibration plots of the training set in 3- and 5-year CSS. (C,D) The calibration plots of the validation set in 3- and 5-year CSS.The area under ROC curve (AUC) was analyzed for both the training and validation set, respectively (Figure 5A–H). Furthermore, the comparisons between the nomograms and TNM stage and SEER stage were performed. The OS and CSS nomograms showed comparable results to TNM stage and SEER stage in both training and validation sets (Table 4). Moreover, the DCA results of nomograms also strengthened the clinical applicability of nomograms from OS and CSS with superiority over TNM stage and SEER stage (Figure 6).
Figure 5
ROC analysis for training and validation sets
(A) The ROC of 3 years OS for training set; (B) the ROC of 5 years OS for training set; (C) the ROC of 3 years OS for validation set; (D) the ROC of 5 years OS for validation set; (E) the ROC of 3 years CSS for training set; (F) the ROC of 5 years CSS for training set; (G) the ROC of 3 years CSS for validation set; and (H) the ROC of 5 years CSS for validation set.
Figure 6
DCA of the training and validation sets for the CSS- and OS-associated nomograms
(A,B) The DCA of nomogram in training set for OS (A) and CSS (B). (C,D) The DCA of nomogram in validation set for OS (C) and CSS (D).
ROC analysis for training and validation sets
(A) The ROC of 3 years OS for training set; (B) the ROC of 5 years OS for training set; (C) the ROC of 3 years OS for validation set; (D) the ROC of 5 years OS for validation set; (E) the ROC of 3 years CSS for training set; (F) the ROC of 5 years CSS for training set; (G) the ROC of 3 years CSS for validation set; and (H) the ROC of 5 years CSS for validation set.
DCA of the training and validation sets for the CSS- and OS-associated nomograms
(A,B) The DCA of nomogram in training set for OS (A) and CSS (B). (C,D) The DCA of nomogram in validation set for OS (C) and CSS (D).
Discussion
The present study established OS and CSS prognostic nomograms for COCApatients derived from the SEER program with favorable discrimination and calibration and comparable predictive capability. In fact, the nomogram highlighted the clinical significance of marital status, race, grade, TNM stage, tumor size, and SEER stage in early-onset COCApatients.The role of marital status in cancer had been previously investigated in SEER program [20]. Married patients were featured by less metastatic diseases, reduced cancer-specific deaths, and more likely to receive definitive therapy [20]. For colon cancer, married patients were more likely to be diagnosed at earlier stage and to receive surgical treatment [21]. Moreover, married patients had significantly lower risk in CSS [21]. Our study also indicated the consistent results.Noteworthy, race, sex, and tumor site were not an independent prognostic variable for early-onset COCApatients in the present study. In fact, race and sex has been viewed as one of the essence variables for cancer treatment [22-24]. Tumor site in CRC had been intensively studied with large population [25,26]. Right-sided colon cancers exhibited increased mortality risk compared with left-sided colon cancers. However, no specific tumor site has been under investigation. Intriguingly, although age was associated with significant prognosis in univariate analysis, it remained insignificant in multivariate analysis, indicating that the subtle stratification between age <30, 30–40, and 40–50 required further investigation.Of note, tumor size was an independent prognostic variable in the nomogram in the present study. In fact, only the tumor >10 cm exhibited significant higher prognostic risk than tumor <2cm whereas the rest stratification remained insignificant. It was possible that the tumor size could be one of the insightful variables for the prognostic risk prediction.Up to now, nomogram statistical tool provided reasonable, reproducible, and rigid algorithms for individualized prognostic assessment. It has been implemented as prognostic indicators for several cancer types including pancreas, gastrointestinal stromal tumor (GIST), and gastric cancer [16,27,28]. In pancreatic cancer, a nomogram constructed by CSS data of 53028 patients diagnosed as pancreatic cancer from the SEER program and eight independent clinical variables (C-index = 0.734) [16]. For a total of 5622 GIST patients, similar nomograms were also established by seven independent clinical variables in both CSS and OS data. Noteworthy, these nomogram exhibited better discrimination power than TNM stage and SEER stage systems [27]. Furthermore, Liu et al. identified a prognostic nomogram for disease specific survival (DSS) of gastric cancerpatients using the SEER program and external validation set [28]. Collectively, incorporation of numerous prognostic-associated clinical variables into nomogram algorithms could display comparable staging system and more disease-specific features.The limitations of the present study were the lack of external clinical data from independent sources and the vacant data on chemotherapy and radiotherapy, as well as the genomic phenotypes in SEER program. Moreover, given the potential confounding factors within the surgical patterns, surgical styles, postoperative complications, and some surgical items remaining contradictory, the COCApatients without surgery or the complete TNM stage data were excluded from the present study.
Conclusion
The nomograms established in the present study provided an alternative tool to both OS and CSS prognostic prediction compared with TNM and SEER stages.
Availability of data and materials
The datasets supporting the conclusion of this article are included within the article.
Human participants and animal rights
This article does not contain any studies with humanparticipants or animals performed by any of the authors.
Supplementary Table S1
Clinicopathological characterization of early-onset colon cancer patients stratified by marital status.
Authors: Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier Journal: Eur J Cancer Date: 2006-08-10 Impact factor: 9.162
Authors: Robert A Meguid; Mark B Slidell; Christopher L Wolfgang; David C Chang; Nita Ahuja Journal: Ann Surg Oncol Date: 2008-07-12 Impact factor: 5.344
Authors: David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem Journal: N Engl J Med Date: 2004-07-22 Impact factor: 91.245
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Zhenxiang Rong; Yi Rong; Yingru Li; Lei Zhang; Jingwen Peng; Baojia Zou; Nan Zhou; Zihao Pan Journal: Front Oncol Date: 2020-02-21 Impact factor: 6.244